The expanding clinical use of C-peptide radioimmunoassay

Marc Rendell

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)105-113
Number of pages9
JournalActa Diabetologica Latina
Issue number2
StatePublished - Jun 1 1983

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'The expanding clinical use of C-peptide radioimmunoassay'. Together they form a unique fingerprint.

Cite this